🔗

Mappings

MONDO

MONDO:0019264 alpha-N-acetylgalactosaminidase deficiency type 3

👪

Inheritance

1

Autosomal recessive HP:0000007

Autosomal recessive inheritance

Show evidence (1 reference)

PMID:31890708 SUPPORT Human Clinical

"Schindler disease is an autosomal recessive, inherited LSD caused by defective or non-existent activity of the enzyme α-N-acetylgalactosaminidase (α-NAGA)"

NAGA deficiency, including the intermediate type 3, is inherited in an autosomal recessive manner.

⚙

Pathophysiology

2

Alpha-N-Acetylgalactosaminidase Deficiency

Biallelic NAGA variants abolish lysosomal alpha-N-acetylgalactosaminidase, the hydrolase that removes terminal alpha-N-acetylgalactosamine residues from glycopeptides and glycolipids.

NAGA hgnc:7631

glycoprotein catabolic process GO:0006516 ↓ DECREASED

Downstream

Lysosomal Glycoconjugate Accumulation Enzyme deficiency leads to lysosomal accumulation of undegraded glycoconjugates.

Show evidence (1 reference)

PMID:14685826 SUPPORT Human Clinical

"Alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency (Schindler/Kanzaki disease) is a clinically and pathologically heterogeneous genetic disease with a wide spectrum including an early onset neuroaxonal dystrophy (Schindler disease) and late onset angiokeratoma corporis diffusum (Kanzaki disease)"

Loss of alpha-NAGA is the primary enzymatic defect across the NAGA-deficiency spectrum, including the intermediate type 3.

Lysosomal Glycoconjugate Accumulation

Failure to cleave terminal alpha-N-acetylgalactosamine causes lysosomal accumulation of incompletely degraded glycoconjugates and cytoplasmic vacuolisation across multiple cell types, driving the intermediate-severity multisystem phenotype.

neuron CL:0000540

Downstream

Intermediate clinical severity Multisystem lysosomal storage produces the intermediate type 3 NAGA-deficiency phenotype.

Seizures Neuronal lysosomal storage contributes to epilepsy in the intermediate NAGA-deficiency phenotype.

Behavioral difficulties Neuronal lysosomal storage contributes to behavioral abnormalities.

Autism Neuronal lysosomal storage contributes to autistic neurodevelopmental features in type 3 disease.

Psychomotor retardation Neuronal lysosomal storage contributes to impaired psychomotor development.

Intellectual disability Neuronal lysosomal storage contributes to impaired cognitive development.

Congenital cataract Multisystem lysosomal storage can include developmental cataract.

Strabismus Multisystem lysosomal storage can include ocular motor abnormalities.

Hypertrophic cardiomyopathy Multisystem lysosomal storage can involve cardiac muscle.

Hepatomegaly Visceral lysosomal storage can enlarge the liver.

Show evidence (1 reference)

PMID:11313741 SUPPORT Human Clinical

"angiokeratoma and clear vacuolisation in various cell types"

Lysosomal substrate storage produces cytoplasmic vacuolisation in multiple cell types.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

10

Cardiovascular 1

Hypertrophic cardiomyopathy Hypertrophic cardiomyopathy HP:0001639

Show evidence (1 reference)

ORPHA:79281 SUPPORT Human Clinical

"HP:0001639 | Hypertrophic cardiomyopathy | Frequent (79-30%)"

Orphanet reports hypertrophic cardiomyopathy as a frequent NAGA deficiency type 3 phenotype.

Digestive 1

Hepatomegaly Hepatomegaly HP:0002240

Show evidence (1 reference)

ORPHA:79281 SUPPORT Human Clinical

"HP:0002240 | Hepatomegaly | Frequent (79-30%)"

Orphanet reports hepatomegaly as a frequent NAGA deficiency type 3 phenotype.

Eye 2

Congenital cataract Developmental cataract HP:0000519

Show evidence (1 reference)

PMID:11313741 SUPPORT Human Clinical

"has congenital cataract, slight motor retardation and secondary demyelinisation"

Congenital cataract was present in an intermediate-form NAGA-deficiency patient.

Strabismus Strabismus HP:0000486

Show evidence (1 reference)

ORPHA:79281 SUPPORT Human Clinical

"HP:0000486 | Strabismus | Very frequent (99-80%)"

Orphanet reports strabismus as a very frequent NAGA deficiency type 3 phenotype.

Nervous System 5

Seizures Seizure HP:0001250

Show evidence (1 reference)

PMID:11313741 SUPPORT Human Clinical

"a very heterogeneous group of patients with various degrees of epilepsy/behavioural difficulties/psychomotor retardation"

Epilepsy is a feature of the intermediate NAGA-deficiency group.

Behavioral difficulties Atypical behavior HP:0000708

Show evidence (1 reference)

PMID:11313741 SUPPORT Human Clinical

"a very heterogeneous group of patients with various degrees of epilepsy/behavioural difficulties/psychomotor retardation"

Behavioral difficulties are part of the intermediate NAGA-deficiency phenotype.

Autism Autism HP:0000717

Show evidence (1 reference)

ORPHA:79281 SUPPORT Human Clinical

"HP:0000717 | Autism | Very frequent (99-80%)"

Orphanet reports autism as a very frequent NAGA deficiency type 3 phenotype.

Psychomotor retardation Global developmental delay HP:0001263

Show evidence (1 reference)

PMID:11313741 SUPPORT Human Clinical

"a very heterogeneous group of patients with various degrees of epilepsy/behavioural difficulties/psychomotor retardation"

Psychomotor retardation is part of the intermediate NAGA-deficiency phenotype.

Intellectual disability Intellectual disability HP:0001249

Show evidence (1 reference)

ORPHA:79281 SUPPORT Human Clinical

"HP:0001249 | Intellectual disability | Very frequent (99-80%)"

Orphanet reports intellectual disability as a very frequent NAGA deficiency type 3 phenotype.

Other 1

Intermediate clinical severity Abnormal nervous system physiology HP:0012638

Show evidence (1 reference)

PMID:31890708 SUPPORT Human Clinical

"Schindler disease type III shows an intermediate phenotype between types I and II"

Establishes type 3 as the intermediate-severity form of NAGA deficiency.

🧬

Genetic Associations

2

NAGA pathogenic variants (Causative)

Gene: NAGA hgnc:7631

Show evidence (1 reference)

PMID:11313741 SUPPORT Human Clinical

"Both sibs are homozygous for the E325K mutation, the same genotype that was found in the most severe form of alpha-NAGA deficiency"

Demonstrates the genotype-phenotype paradox underlying the heterogeneous type 3 presentation.

Genotype-phenotype discordance (ModifierOf)

Gene: NAGA hgnc:7631

Show evidence (1 reference)

PMID:11313741 SUPPORT Human Clinical

"suggest that factors or genes other than alpha-NAGA contribute to the clinical heterogeneity"

Supports a modifier contribution to the variable type 3 phenotype.

💊

Medical Actions

1

Supportive and Symptomatic Care

Action: supportive care MAXO:0000950

No disease-modifying therapy exists; management is supportive and symptomatic, including anticonvulsants for seizures and developmental support.

Show evidence (1 reference)

PMID:31890708 SUPPORT Human Clinical

"The only treatment for this disease consists of support measures and symptomatic treatment"

Supportive and symptomatic care is the only established management.

🔬

Biochemical Markers

1

Glycopeptiduria and oligosacchariduria (INCREASED)

Context: Urinary excretion of incompletely degraded glycopeptides / oligosaccharides reflecting impaired alpha-NAGA-mediated glycoconjugate catabolism.

Show evidence (1 reference)

PMID:31890708 SUPPORT Human Clinical

"urine tests can identify glycopeptiduria"

Glycopeptiduria is the characteristic urinary biochemical abnormality across NAGA deficiency.

{ }

Source YAML

click to show

name: NAGA Deficiency Type 3
creation_date: "2026-06-13T00:00:00Z"
description: >-
  Alpha-N-acetylgalactosaminidase deficiency type 3 (Schindler disease type III) is the
  intermediate form of NAGA deficiency, an autosomal recessive lysosomal storage disorder
  caused by biallelic NAGA variants that abolish lysosomal alpha-N-acetylgalactosaminidase.
  Enzyme deficiency causes accumulation of incompletely degraded glycoconjugates bearing
  terminal alpha-N-acetylgalactosamine, producing a clinically heterogeneous phenotype of
  intermediate severity between infantile Schindler disease (type 1) and adult Kanzaki
  disease (type 2), with variable epilepsy, behavioral difficulties, and psychomotor
  retardation. The extreme clinical heterogeneity among patients sharing identical NAGA
  genotypes implies that factors beyond NAGA modify disease expression.
synonyms:
- alpha-N-acetylgalactosaminidase deficiency type 3
- Schindler disease type III
- intermediate Schindler phenotype
- NAGA deficiency, intermediate
category: Mendelian
disease_term:
  preferred_term: alpha-N-acetylgalactosaminidase deficiency type 3
  term:
    id: MONDO:0019264
    label: alpha-N-acetylgalactosaminidase deficiency type 3
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0019264
      label: alpha-N-acetylgalactosaminidase deficiency type 3
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
parents:
- Lysosomal Storage Disorder
inheritance:
- name: Autosomal recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:31890708
    reference_title: "A New Case of Schindler Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Schindler disease is an autosomal recessive, inherited LSD caused by defective or non-existent activity of the enzyme α-N-acetylgalactosaminidase (α-NAGA)"
    explanation: NAGA deficiency, including the intermediate type 3, is inherited in an autosomal recessive manner.
pathophysiology:
- name: Alpha-N-Acetylgalactosaminidase Deficiency
  conforms_to: "lysosomal_substrate_accumulation#Lysosomal Hydrolase or Cofactor Deficiency"
  description: >-
    Biallelic NAGA variants abolish lysosomal alpha-N-acetylgalactosaminidase, the hydrolase
    that removes terminal alpha-N-acetylgalactosamine residues from glycopeptides and
    glycolipids.
  gene:
    preferred_term: NAGA
    term:
      id: hgnc:7631
      label: NAGA
  biological_processes:
  - preferred_term: glycoprotein catabolic process
    term:
      id: GO:0006516
      label: glycoprotein catabolic process
    modifier: DECREASED
  evidence:
  - reference: PMID:14685826
    reference_title: "Structural and immunocytochemical studies on alpha-N-acetylgalactosaminidase deficiency (Schindler/Kanzaki disease)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency (Schindler/Kanzaki disease) is a clinically and pathologically heterogeneous genetic disease with a wide spectrum including an early onset neuroaxonal dystrophy (Schindler disease) and late onset angiokeratoma corporis diffusum (Kanzaki disease)"
    explanation: Loss of alpha-NAGA is the primary enzymatic defect across the NAGA-deficiency spectrum, including the intermediate type 3.
  downstream:
  - target: Lysosomal Glycoconjugate Accumulation
    description: Enzyme deficiency leads to lysosomal accumulation of undegraded glycoconjugates.
- name: Lysosomal Glycoconjugate Accumulation
  conforms_to: "lysosomal_substrate_accumulation#Lysosomal Substrate Accumulation"
  description: >-
    Failure to cleave terminal alpha-N-acetylgalactosamine causes lysosomal accumulation of
    incompletely degraded glycoconjugates and cytoplasmic vacuolisation across multiple cell
    types, driving the intermediate-severity multisystem phenotype.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:11313741
    reference_title: "Human alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency: no association with neuroaxonal dystrophy?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "angiokeratoma and clear vacuolisation in various cell types"
    explanation: Lysosomal substrate storage produces cytoplasmic vacuolisation in multiple cell types.
  downstream:
  - target: Intermediate clinical severity
    description: Multisystem lysosomal storage produces the intermediate type 3 NAGA-deficiency phenotype.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Seizures
    description: Neuronal lysosomal storage contributes to epilepsy in the intermediate NAGA-deficiency phenotype.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Behavioral difficulties
    description: Neuronal lysosomal storage contributes to behavioral abnormalities.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Autism
    description: Neuronal lysosomal storage contributes to autistic neurodevelopmental features in type 3 disease.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Psychomotor retardation
    description: Neuronal lysosomal storage contributes to impaired psychomotor development.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Intellectual disability
    description: Neuronal lysosomal storage contributes to impaired cognitive development.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Congenital cataract
    description: Multisystem lysosomal storage can include developmental cataract.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Strabismus
    description: Multisystem lysosomal storage can include ocular motor abnormalities.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Hypertrophic cardiomyopathy
    description: Multisystem lysosomal storage can involve cardiac muscle.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Hepatomegaly
    description: Visceral lysosomal storage can enlarge the liver.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
phenotypes:
- name: Intermediate clinical severity
  description: >-
    Type 3 is classically an intermediate phenotype between the severe infantile (type 1) and
    mild adult (type 2) forms.
  phenotype_term:
    preferred_term: Abnormal nervous system physiology
    term:
      id: HP:0012638
      label: Abnormal nervous system physiology
  evidence:
  - reference: PMID:31890708
    reference_title: "A New Case of Schindler Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Schindler disease type III shows an intermediate phenotype between types I and II"
    explanation: Establishes type 3 as the intermediate-severity form of NAGA deficiency.
- name: Seizures
  description: Epilepsy of variable degree in the intermediate group.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:11313741
    reference_title: "Human alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency: no association with neuroaxonal dystrophy?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a very heterogeneous group of patients with various degrees of epilepsy/behavioural difficulties/psychomotor retardation"
    explanation: Epilepsy is a feature of the intermediate NAGA-deficiency group.
- name: Behavioral difficulties
  description: Behavioral abnormalities in the intermediate group.
  phenotype_term:
    preferred_term: Atypical behavior
    term:
      id: HP:0000708
      label: Atypical behavior
  evidence:
  - reference: PMID:11313741
    reference_title: "Human alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency: no association with neuroaxonal dystrophy?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a very heterogeneous group of patients with various degrees of epilepsy/behavioural difficulties/psychomotor retardation"
    explanation: Behavioral difficulties are part of the intermediate NAGA-deficiency phenotype.
- name: Autism
  description: Autism is reported by Orphanet as a very frequent neurodevelopmental feature of NAGA deficiency type 3.
  phenotype_term:
    preferred_term: Autism
    term:
      id: HP:0000717
      label: Autism
  evidence:
  - reference: ORPHA:79281
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "HP:0000717 | Autism | Very frequent (99-80%)"
    explanation: Orphanet reports autism as a very frequent NAGA deficiency type 3 phenotype.
- name: Psychomotor retardation
  description: Variable psychomotor / global developmental delay.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:11313741
    reference_title: "Human alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency: no association with neuroaxonal dystrophy?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a very heterogeneous group of patients with various degrees of epilepsy/behavioural difficulties/psychomotor retardation"
    explanation: Psychomotor retardation is part of the intermediate NAGA-deficiency phenotype.
- name: Intellectual disability
  description: Intellectual disability is reported as a very frequent feature of the NAGA deficiency type 3 phenotype.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: ORPHA:79281
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "HP:0001249 | Intellectual disability | Very frequent (99-80%)"
    explanation: Orphanet reports intellectual disability as a very frequent NAGA deficiency type 3 phenotype.
- name: Congenital cataract
  description: Congenital cataract reported in an intermediate-form index patient.
  phenotype_term:
    preferred_term: Congenital cataract
    term:
      id: HP:0000519
      label: Developmental cataract
  evidence:
  - reference: PMID:11313741
    reference_title: "Human alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency: no association with neuroaxonal dystrophy?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "has congenital cataract, slight motor retardation and secondary demyelinisation"
    explanation: Congenital cataract was present in an intermediate-form NAGA-deficiency patient.
- name: Strabismus
  description: Ocular misalignment reported as a very frequent feature in Orphanet for NAGA deficiency type 3.
  phenotype_term:
    preferred_term: Strabismus
    term:
      id: HP:0000486
      label: Strabismus
  evidence:
  - reference: ORPHA:79281
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "HP:0000486 | Strabismus | Very frequent (99-80%)"
    explanation: Orphanet reports strabismus as a very frequent NAGA deficiency type 3 phenotype.
- name: Hypertrophic cardiomyopathy
  description: Cardiac hypertrophic involvement reported in the type 3 NAGA-deficiency phenotype spectrum.
  phenotype_term:
    preferred_term: Hypertrophic cardiomyopathy
    term:
      id: HP:0001639
      label: Hypertrophic cardiomyopathy
  evidence:
  - reference: ORPHA:79281
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "HP:0001639 | Hypertrophic cardiomyopathy | Frequent (79-30%)"
    explanation: Orphanet reports hypertrophic cardiomyopathy as a frequent NAGA deficiency type 3 phenotype.
- name: Hepatomegaly
  description: Liver enlargement reported in the type 3 NAGA-deficiency phenotype spectrum.
  phenotype_term:
    preferred_term: Hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
  evidence:
  - reference: ORPHA:79281
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "HP:0002240 | Hepatomegaly | Frequent (79-30%)"
    explanation: Orphanet reports hepatomegaly as a frequent NAGA deficiency type 3 phenotype.
genetic:
- name: NAGA pathogenic variants
  gene_term:
    preferred_term: NAGA
    term:
      id: hgnc:7631
      label: NAGA
  association: Causative
  notes: >-
    Biallelic loss-of-function NAGA variants cause type 3. Notably, the same E325K genotype
    associated with severe infantile disease can present as an intermediate or even
    asymptomatic phenotype, indicating modifiers beyond NAGA.
  evidence:
  - reference: PMID:11313741
    reference_title: "Human alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency: no association with neuroaxonal dystrophy?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Both sibs are homozygous for the E325K mutation, the same genotype that was found in the most severe form of alpha-NAGA deficiency"
    explanation: Demonstrates the genotype-phenotype paradox underlying the heterogeneous type 3 presentation.
- name: Genotype-phenotype discordance
  gene_term:
    preferred_term: NAGA
    term:
      id: hgnc:7631
      label: NAGA
  association: ModifierOf
  notes: >-
    Extreme clinical heterogeneity among patients with identical NAGA genotypes suggests
    contributing factors or genes beyond NAGA.
  evidence:
  - reference: PMID:11313741
    reference_title: "Human alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency: no association with neuroaxonal dystrophy?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "suggest that factors or genes other than alpha-NAGA contribute to the clinical heterogeneity"
    explanation: Supports a modifier contribution to the variable type 3 phenotype.
biochemical:
- name: Glycopeptiduria and oligosacchariduria
  presence: INCREASED
  context: >-
    Urinary excretion of incompletely degraded glycopeptides / oligosaccharides reflecting
    impaired alpha-NAGA-mediated glycoconjugate catabolism.
  evidence:
  - reference: PMID:31890708
    reference_title: "A New Case of Schindler Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "urine tests can identify glycopeptiduria"
    explanation: Glycopeptiduria is the characteristic urinary biochemical abnormality across NAGA deficiency.
diagnosis:
- name: Enzyme assay and molecular testing
  description: >-
    Diagnosis rests on demonstrating deficient alpha-NAGA activity, supportive urinary
    glycopeptiduria, and confirmatory NAGA molecular testing.
  diagnosis_term:
    preferred_term: clinical laboratory procedure
    term:
      id: MAXO:0000006
      label: clinical laboratory procedure
  evidence:
  - reference: PMID:31890708
    reference_title: "A New Case of Schindler Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Enzymatic analysis through a blood test shows diminished α-NAGA activity"
    explanation: Reduced alpha-NAGA enzyme activity is the key biochemical diagnostic test.
treatments:
- name: Supportive and Symptomatic Care
  description: >-
    No disease-modifying therapy exists; management is supportive and symptomatic, including
    anticonvulsants for seizures and developmental support.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:31890708
    reference_title: "A New Case of Schindler Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The only treatment for this disease consists of support measures and symptomatic treatment"
    explanation: Supportive and symptomatic care is the only established management.
references:
- reference: PMID:39426251
  title: "Assessment of genes involved in lysosomal diseases using the ClinGen clinical validity framework."
- reference: PMID:8782044
  title: "Human alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency: new mutations and the paradox between genotype and phenotype."

📚

References & Deep Research

References

2

PMID:39426251

Assessment of genes involved in lysosomal diseases using the ClinGen clinical validity framework.

No top-level findings curated for this source.

PMID:8782044

Human alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency: new mutations and the paradox between genotype and phenotype.

No top-level findings curated for this source.

Deep Research

1

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 38 citations 2026-06-13T16:25:27.977931

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: NAGA Deficiency Type 3
MONDO ID: (if available)
Category: Mendelian

Research Objectives

Please provide a comprehensive research report on NAGA Deficiency Type 3 covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive research report: NAGA Deficiency Type 3 (Schindler disease type III)

Executive summary

“NAGA Deficiency Type 3” corresponds to Schindler disease type III, an ultra-rare autosomal recessive lysosomal storage disorder caused by biallelic pathogenic variants in NAGA leading to deficiency of lysosomal α-N-acetylgalactosaminidase (α‑NAGA; also called galactosidase B). Type III is classically described as an intermediate phenotype between severe infantile neuroaxonal dystrophy (type I) and adult-onset Kanzaki disease (type II). A 2024 ClinGen lysosomal-disease curation supports a definitive NAGA–disease relationship and explicitly maps the disease to MONDO:0017779. (groopman2024assessmentofgenes pages 8-11, castro2019anewcase pages 1-3, sakuraba2004structuralandimmunocytochemical pages 1-2)

1. Disease information

1.1 Overview

Schindler disease is a lysosomal storage disorder due to deficient/absent α‑NAGA activity, with lysosomal accumulation of incompletely degraded glycoconjugates and highly variable clinical expressivity, ranging from severe infantile neurodegeneration to mild adult angiokeratoma/lymphoedema phenotypes. (castro2019anewcase pages 1-3, bakker2001humanαnacetylgalactosaminidase(αnaga) pages 1-2)

Type III is described as intermediate between types I and II in multiple sources. (castro2019anewcase pages 1-3, sakuraba2004structuralandimmunocytochemical pages 1-2)

1.2 Key identifiers

MONDO: MONDO:0017779 (α‑N‑acetylgalactosaminidase deficiency) as used in ClinGen lysosomal disease gene curation. (groopman2024assessmentofgenes pages 8-11)

Note: OMIM/Orphanet/ICD/MeSH codes were not present in the retrieved full-text excerpts used for evidence extraction; they should be added from OMIM/Orphanet/MONDO cross-references during downstream curation (not inferable from the cited excerpts without external lookup). (groopman2024assessmentofgenes pages 8-11)

1.3 Synonyms / alternative names

Common names used in the literature: - Schindler disease (types I/III) (castro2019anewcase pages 1-3, sakuraba2004structuralandimmunocytochemical pages 1-2) - Kanzaki disease (Schindler disease type II) (castro2019anewcase pages 1-3, sakuraba2004structuralandimmunocytochemical pages 1-2) - α‑N‑acetylgalactosaminidase deficiency / α‑NAGA deficiency (keulemans1996humanalphanacetylgalactosaminidase(alphanaga) pages 1-2, bakker2001humanαnacetylgalactosaminidase(αnaga) pages 1-2) - Schindler/Kanzaki disease (sakuraba2004structuralandimmunocytochemical pages 1-2)

1.4 Evidence type (individual vs aggregated)

The condition is so rare that much of the literature consists of individual patients and families, including genotype–phenotype analyses across a small number of reported cases. (bakker2001humanαnacetylgalactosaminidase(αnaga) pages 1-2, sakuraba2004structuralandimmunocytochemical pages 1-2)

2. Etiology

2.1 Primary causal factors

Genetic cause: biallelic pathogenic variants in NAGA cause deficient lysosomal α‑NAGA activity. (castro2019anewcase pages 1-3, bakker2001humanαnacetylgalactosaminidase(αnaga) pages 1-2)
Pathogenic mechanism: loss of α‑NAGA activity leads to impaired hydrolysis of specific terminal residues and accumulation of undegraded substrates in cells; one clinical summary describes accumulation of “large molecules such as galactose oligosaccharides, galactomannans and galactolipids” with systemic manifestations. (castro2019anewcase pages 1-3)

2.2 Risk factors

Family history / autosomal recessive inheritance: reviewed sources describe autosomal recessive inheritance with a 25% recurrence risk for carrier couples. (asadi2021theroleof pages 1-3)

2.3 Protective factors / gene–environment interactions

No validated protective factors or gene–environment interactions were identified in the retrieved disease-specific evidence.

3. Phenotypes

3.1 Phenotype spectrum and type definitions

A widely used clinical categorization includes: - Type I: early-onset severe phenotype described as infantile neuroaxonal dystrophy. (sakuraba2004structuralandimmunocytochemical pages 1-2) - Type II (Kanzaki disease): adult-onset mild phenotype with angiokeratoma corporis diffusum and vacuolization, often without overt CNS manifestations. (castro2019anewcase pages 1-3, sakuraba2004structuralandimmunocytochemical pages 1-2) - Type III: intermediate phenotype between types I and II. (castro2019anewcase pages 1-3, sakuraba2004structuralandimmunocytochemical pages 1-2)

Bakker et al. (2001) further describe an “intermediate group” characterized by epilepsy, behavioral problems and psychomotor retardation among reported cases, illustrating variability and partial overlap with the type‑III concept. (bakker2001humanαnacetylgalactosaminidase(αnaga) pages 1-2)

3.2 Example clinical features reported across the spectrum

Dermatologic/vascular: angiokeratoma corporis diffusum; vacuolization in dermal and endothelial cell types in milder phenotypes. (keulemans1996humanalphanacetylgalactosaminidase(alphanaga) pages 1-2, castro2019anewcase pages 1-3)
Lymphatic: chronic lymphoedema (adult phenotypes). (castro2019anewcase pages 1-3)
Peripheral nervous system / sensory: peripheral neuropathy and sensorineural hearing loss reported in adult phenotypes. (castro2019anewcase pages 1-3)
Neurodevelopmental/neurologic (more severe/intermediate): seizures/epilepsy, psychomotor delay, behavioral problems reported in intermediate/severe presentations. (bakker2001humanαnacetylgalactosaminidase(αnaga) pages 1-2, asadi2021theroleof pages 1-3)

3.3 Suggested HPO terms (based on reported clinical features)

(terms are suggestions for knowledge-base annotation; frequencies are not well-established due to ultra-rare case numbers) - Angiokeratoma: HP:0001012 - Lymphedema: HP:0001004 - Peripheral neuropathy: HP:0009830 - Sensorineural hearing impairment: HP:0000407 - Seizures: HP:0001250 - Global developmental delay / psychomotor delay: HP:0001263 - Behavioral abnormality: HP:0000708

Evidence base for these phenotype components is primarily case-based. (bakker2001humanαnacetylgalactosaminidase(αnaga) pages 1-2, keulemans1996humanalphanacetylgalactosaminidase(alphanaga) pages 1-2, castro2019anewcase pages 1-3)

4. Genetic / molecular information

4.1 Causal gene

NAGA (α‑N‑acetylgalactosaminidase); ClinGen LD GCEP classified the gene–disease relationship as definitive, with phenotypic variability and reports of clinically unaffected individuals despite enzyme deficiency. (groopman2024assessmentofgenes pages 8-11)

4.2 Pathogenic variants (examples in primary literature)

Primary literature and case-based studies report multiple variants across the phenotypic spectrum: - E325K: associated with severe infantile neuroaxonal dystrophy in early reports but also found in less severe/asymptomatic individuals (genotype–phenotype paradox). (bakker2001humanαnacetylgalactosaminidase(αnaga) pages 1-2, bakker2001humanαnacetylgalactosaminidase(αnaga) pages 4-5) - R329W: identified as a causal lesion for adult angiokeratoma corporis diffusum with glycopeptiduria; transient expression produced an immunoreactive protein lacking detectable enzyme activity (loss of function). (wang1994themolecularlesion pages 1-2) - R329Q: reported among Kanzaki/type II patients. (sakuraba2004structuralandimmunocytochemical pages 1-2) - E193X / p.Glu193*: a nonsense/null allele reported in mild late-onset cases, illustrating paradoxical genotype–phenotype correlation. (bakker2001humanαnacetylgalactosaminidase(αnaga) pages 4-5) - c.577G>T (p.Glu193*): identified in an adult case report confirming Schindler disease. (castro2019anewcase pages 1-3)

4.3 Genotype–phenotype complexity and modifiers

Multiple sources emphasize extreme heterogeneity and poor correlation between genotype, enzyme deficiency, and clinical severity, with suggestions that other factors/genes influence expressivity. (keulemans1996humanalphanacetylgalactosaminidase(alphanaga) pages 1-2, bakker2001humanαnacetylgalactosaminidase(αnaga) pages 1-2)

5. Environmental information

No disease-specific non-genetic environmental contributors were identified in the retrieved evidence; the disorder is primarily Mendelian/enzymatic.

6. Mechanism / pathophysiology

6.1 Core defect and causal chain

1) Biallelic NAGA variants → 2) deficient lysosomal α‑NAGA activity → 3) storage of incompletely degraded glycoconjugates with characteristic glycopeptiduria/oligosacchariduria → 4) multisystem cellular dysfunction manifesting variably as neurologic disease (severe/intermediate forms), dermatologic/vascular lesions and lymphatic involvement (milder adult forms). (castro2019anewcase pages 1-3, bakker2001humanαnacetylgalactosaminidase(αnaga) pages 1-2)

6.2 Biochemical abnormalities and stored material

Urinary abnormalities include sialylglycopeptides of the O-linked type (Ser/Thr-linked GalNAc) detected by urinary oligosaccharide analysis. (bakker2001humanαnacetylgalactosaminidase(αnaga) pages 1-2)
Immunocytochemical work supports lysosomal accumulation of Tn-antigen in Kanzaki patient fibroblasts, despite urinary excretion being dominated by sialylglycopeptides, highlighting complexity of storage biology. (sakuraba2004structuralandimmunocytochemical pages 1-2)

6.3 Suggested GO biological process terms (mechanism-oriented)

Lysosomal catabolic process: GO:0044248 (suggested)
Glycoprotein catabolic process: GO:0006516 (suggested)
Glycosphingolipid catabolic process: GO:0046517 (suggested)
Lysosome organization / function: GO:0007040 (suggested)

6.4 Suggested Cell Ontology (CL) terms for implicated cell types

Based on reported vacuolization/storage in dermal and endothelial/lymphatic cells: - Endothelial cell: CL:0000115 (suggested) (keulemans1996humanalphanacetylgalactosaminidase(alphanaga) pages 1-2) - Fibroblast: CL:0000057 (suggested) (keulemans1996humanalphanacetylgalactosaminidase(alphanaga) pages 1-2)

7. Anatomical structures affected

Reported manifestations implicate: - Skin (angiokeratomas; dermal cellular vacuolization). (keulemans1996humanalphanacetylgalactosaminidase(alphanaga) pages 1-2, castro2019anewcase pages 1-3) - Peripheral nervous system (polyneuropathy). (castro2019anewcase pages 1-3) - Inner ear/auditory system (sensorineural hearing loss). (castro2019anewcase pages 1-3) - Lymphatic system (chronic lymphoedema). (castro2019anewcase pages 1-3) - Central nervous system prominently in severe infantile and intermediate phenotypes (neuroaxonal dystrophy, seizures/developmental regression). (sakuraba2004structuralandimmunocytochemical pages 1-2, castro2019anewcase pages 1-3)

Suggested UBERON terms (examples): - Skin: UBERON:0002097 - Peripheral nervous system: UBERON:0000010 - Inner ear: UBERON:0001844 - Lymphatic system: UBERON:0006558 - Brain: UBERON:0000955

8. Temporal development

Type I onset: one clinical summary reports onset “around the second year of life” and death “before the age of 6 years.” (castro2019anewcase pages 1-3)
Type II onset: adult onset (Kanzaki). (castro2019anewcase pages 1-3, sakuraba2004structuralandimmunocytochemical pages 1-2)
Type III: intermediate (timing variable; described between types I and II). (castro2019anewcase pages 1-3, sakuraba2004structuralandimmunocytochemical pages 1-2)

9. Inheritance and population

Inheritance: autosomal recessive. (asadi2021theroleof pages 1-3)
Rarity/case counts: fewer than ~20 cases described to 2019 in one case report; earlier literature summarizes 11 known individuals (2001) and 12 patients from eight families (2004). (castro2019anewcase pages 1-3, bakker2001humanαnacetylgalactosaminidase(αnaga) pages 1-2, sakuraba2004structuralandimmunocytochemical pages 1-2)
Penetrance/expressivity: clinically unaffected individuals with the same genotype and enzyme deficiency have been reported (suggesting modifiers/incomplete penetrance). (groopman2024assessmentofgenes pages 8-11, bakker2001humanαnacetylgalactosaminidase(αnaga) pages 1-2)

10. Diagnostics

A typical diagnostic workflow uses biochemical screening plus confirmatory enzyme and genetic testing.

Diagnostic domain	Specimen type(s)	Method	Principal finding / biomarker	Quantitative or technical detail	Example clinical use	Key reference (year; DOI/URL)	Citation
Urinary screening	24 h urine	Thin-layer chromatography after desalting, followed by orcinol staining	Abnormal urinary oligosaccharides / sialylglycopeptides of the O-linked type with Ser/Thr-linked GalNAc	Qualitative TLC pattern; used as initial biochemical screen	Detect characteristic glycopeptiduria in suspected α-NAGA deficiency	Bakker et al. 2001; https://doi.org/10.1038/sj.ejhg.5200598	(bakker2001humanαnacetylgalactosaminidase(αnaga) pages 1-2)
Urinary biomarker profiling	Urine	Targeted LC-MS/MS glycomic profiling	Elevated GalNAc-threonine, GalNAc-serine; sometimes hex3-hexNAc3	GalNAc-threonine Z ≈ 80; GalNAc-serine Z ≈ 20; abnormal oligosaccharide peaks often ≥2 orders of magnitude above negatives	Sensitive modern biochemical detection and differential diagnosis among lysosomal storage disorders	Mak & Cowan 2021; https://doi.org/10.1016/j.ymgme.2021.08.006	(mak2021detectinglysosomalstorage pages 8-9, mak2021detectinglysosomalstorage media 8ee1fda0)
Enzyme confirmation	Leukocytes	α-NAGA enzyme activity assay	Markedly reduced or undetectable α-N-acetylgalactosaminidase activity	Profound deficiency reported; no uniform numeric cutoff provided in extracted text	Biochemical confirmation after urine screening	Bakker et al. 2001; https://doi.org/10.1038/sj.ejhg.5200598	(bakker2001humanαnacetylgalactosaminidase(αnaga) pages 1-2)
Enzyme confirmation	Cultured skin fibroblasts	α-NAGA enzyme activity assay	Profound fibroblast α-NAGA deficiency	Assays performed in cultured fibroblasts; no numeric activity units captured in extracted text	Confirms diagnosis, especially in atypical cases	Keulemans et al. 1996; https://doi.org/10.1136/jmg.33.6.458	(keulemans1996humanalphanacetylgalactosaminidase(alphanaga) pages 1-2)
Cellular storage demonstration	Cultured skin fibroblasts	Lectin histochemistry / immunocytochemical detection	Intralysosomal storage with αGalNAc-reactive material; Tn-antigen accumulation in Kanzaki fibroblasts	Qualitative cellular localization evidence	Supports mechanism and complements enzyme/genetic findings	Keulemans et al. 1996; https://doi.org/10.1136/jmg.33.6.458; Sakuraba et al. 2004; https://doi.org/10.1007/s10038-003-0098-z	(keulemans1996humanalphanacetylgalactosaminidase(alphanaga) pages 1-2, sakuraba2004structuralandimmunocytochemical pages 1-2)
Blood-based enzymatic testing	Blood	Blood enzyme assay for α-NAGA activity	Diminished α-NAGA activity	Described as enzymatic analysis through a blood test; no extracted numeric threshold	Practical clinical test in case workup	Castro et al. 2019; https://doi.org/10.12890/2019_001269	(castro2019anewcase pages 1-3, castro2019anewcase pages 3-3)
Molecular confirmation	Leukocyte DNA or fibroblast DNA	PCR amplification and sequencing of NAGA exons/intron boundaries	Pathogenic NAGA variants confirm diagnosis	Nine exons sequenced; example 351-bp PCR fragment for E325K testing, with normal TaqI digestion into 174 and 177 bp fragments abolished by mutation	Gold-standard confirmatory diagnosis; family testing	Bakker et al. 2001; https://doi.org/10.1038/sj.ejhg.5200598	(bakker2001humanαnacetylgalactosaminidase(αnaga) pages 1-2)
Molecular confirmation	Blood-derived DNA	PCR / targeted genetic testing	c.577G>T (p.Glu193*) identified in a confirmed case	Variant-level confirmation of Schindler disease	Confirms diagnosis and distinguishes from phenocopies such as Fabry disease	Castro et al. 2019; https://doi.org/10.12890/2019_001269	(castro2019anewcase pages 1-3, castro2019anewcase pages 3-3)
Broad diagnostic workflow	Plasma, peripheral blood leukocytes, dried blood spots, cultured skin fibroblasts, urine	Stepwise biochemical plus genetic testing	Abnormal biochemical findings should be confirmed by enzymatic assay and targeted/NGS molecular testing	Lab-specific protocols and age-specific reference ranges may vary	Real-world implementation for lysosomal disease workup, including NAGA deficiency	Lange et al. 2024; https://doi.org/10.51847/isa3beaurx	(lange2024systematicdiagnosisof pages 6-7)

Table: This table summarizes the main diagnostic specimens, methods, and biomarkers reported for Schindler disease / NAGA deficiency. It highlights both classic biochemical workflows and newer LC-MS/MS glycomic profiling findings that support diagnosis and differential testing.

Key real-world diagnostic implementations include: - Genetic testing (PCR/sequencing) as confirmatory “gold standard” in a published case report. (castro2019anewcase pages 1-3) - Modern LC-MS/MS urine glycomic profiling, which can detect Schindler disease biomarkers with large Z-scores (e.g., GalNAc-threonine Z≈80; GalNAc-serine Z≈20) and provides multiplex differential diagnosis across lysosomal disorders. (mak2021detectinglysosomalstorage pages 8-9, mak2021detectinglysosomalstorage media 8ee1fda0)

11. Outcome / prognosis

Type I prognosis: death often before age 6 per case-based summary; severe neurologic progression. (castro2019anewcase pages 1-3)
Prognostic modifier: blood group A reported to have worse prognosis in one case report review. (castro2019anewcase pages 1-3)
Clinical heterogeneity: ranges from severe neurologic disability (including vegetative state in some reports) to asymptomatic individuals detected by family screening. (bakker2001humanαnacetylgalactosaminidase(αnaga) pages 4-5, bakker2001humanαnacetylgalactosaminidase(αnaga) pages 5-6)

12. Treatment

12.1 Current standard of care

No established disease-modifying therapy; care is described as supportive and symptomatic, often requiring a multidisciplinary team. (asadi2021theroleof pages 3-4, castro2019anewcase pages 1-3)

12.2 Emerging/experimental approaches

Pharmacological chaperones: proposed as potential therapeutic agents (not yet established in the excerpts; no named compounds or trial results in retrieved text). (castro2019anewcase pages 1-3)
Hematopoietic cell transplant (HCT): a 2020 review states HCT has not been attempted for Schindler disease to date, but could be considered conceptually to alter natural history in lysosomal diseases, particularly for neurologic involvement (via CNS engraftment/cross-correction). (naumchik2020theroleof pages 7-9)
Enzyme engineering/ERT concepts: research on a modified NAGA enzyme for Fabry disease demonstrates engineering for M6P-mediated uptake and in vivo substrate clearance in mice, offering methodological precedent for lysosomal enzyme therapeutic development (though not Schindler-specific therapy). (tajima2009useofa pages 1-2)

Suggested MAXO terms (examples): - Supportive care: MAXO:0000747 (suggested) - Genetic counseling: MAXO:0000079 (suggested) - Enzyme replacement therapy: MAXO:0000475 (suggested, experimental/not established for Schindler) - Hematopoietic stem cell transplantation: MAXO:0000647 (suggested, not yet attempted for Schindler per cited review)

13. Prevention

Primary prevention is not applicable in the usual sense for a Mendelian enzyme deficiency, but reproductive risk reduction is feasible via carrier testing and genetic counseling, given autosomal recessive inheritance with ~25% recurrence risk. (asadi2021theroleof pages 1-3)
Secondary prevention: earlier recognition through biochemical screening (urine oligosaccharides; LC-MS/MS panels) and confirmatory genetics may shorten diagnostic delay. (bakker2001humanαnacetylgalactosaminidase(αnaga) pages 1-2, mak2021detectinglysosomalstorage pages 8-9)

14. Other species / natural disease

No naturally occurring veterinary disease counterpart was identified in the retrieved evidence.

However, α‑NAGAL function is studied across species: - Schistosoma mansoni SmNAGAL is functionally important for motility and egg production (siRNA and CRISPR perturbation), and the authors explicitly relate human α‑NAGAL/α‑GAL mutations to Schindler/Kanzaki and Fabry diseases. (hulme2022schistosomamansoniαnacetylgalactosaminidase pages 1-2)

15. Model organisms and experimental systems

Non-human animal model evidence contributed to ClinGen’s definitive classification for NAGA–disease; details of the species/model are not given in the extracted excerpt. (groopman2024assessmentofgenes pages 8-11)
Structural templates: chicken α‑NAGA structures have been used for homology modeling of the human enzyme. (sakuraba2004structuralandimmunocytochemical pages 3-5)
Expression systems: recombinant insect-cell expression has been used for human α‑NAGA structural studies. (clark2009the1.9a pages 1-2)
Mouse model (therapeutic development context): modified NAGA used in Fabry model mice prevented substrate accumulation in multiple organs (methodological precedent for lysosomal enzyme therapeutics). (tajima2009useofa pages 1-2)

Recent developments and latest research (prioritizing 2023–2024)

1) ClinGen LD GCEP 2024 assessment: NAGA–α‑NAGA deficiency is curated as definitive, mapped to MONDO:0017779, with explicit note of phenotypic variability and reports of clinically unaffected individuals sharing genotype and enzyme deficiency, supporting modifier/incomplete penetrance hypotheses. Publication: Nov 2024, Molecular Genetics and Metabolism. URL: https://doi.org/10.1016/j.ymgme.2024.108593. (groopman2024assessmentofgenes pages 8-11)

2) Diagnostic technology trend (LC-MS/MS panels): targeted urine glycomic profiling provides multiplex detection and quantitative readouts (Z-scores) for oligosaccharidoses, including Schindler disease (although the key paper retrieved is 2021, it reflects current clinical laboratory direction and is commonly implemented in contemporary biochemical genetics practice). URL: https://doi.org/10.1016/j.ymgme.2021.08.006. (mak2021detectinglysosomalstorage pages 8-9, mak2021detectinglysosomalstorage media 8ee1fda0)

Current applications and real-world implementations

Confirmatory genetic diagnosis by PCR/sequencing in clinical case practice. (castro2019anewcase pages 1-3)
Biochemical genetics laboratory workflows using urine oligosaccharides and enzyme assays, increasingly augmented by LC-MS/MS glycomics for differential diagnosis. (bakker2001humanαnacetylgalactosaminidase(αnaga) pages 1-2, mak2021detectinglysosomalstorage pages 8-9)
Natural history/registry-type data collection via an observational cohort study covering glycoproteinoses including Schindler disease:
ClinicalTrials.gov NCT01891422, “Longitudinal Studies of the Glycoproteinoses,” observational; enrollment 100; aims include progression tracking, supportive therapy documentation, and genotype–phenotype correlations; includes biospecimens (plasma, white cells, fibroblasts, urine where applicable). (NCT01891422 chunk 1)

Expert opinions and analysis (authoritative sources)

The ClinGen curation emphasizes that while the biochemical relationship of NAGA variants to enzyme deficiency is definitive, clinical impact can be inconsistent, highlighting uncertainty in penetrance and the likely contribution of modifiers. (groopman2024assessmentofgenes pages 8-11)
Multiple primary studies emphasize a genotype–phenotype paradox, with null alleles (e.g., E193X) reported in mild phenotypes and the same missense genotype (e.g., E325K) associated with both severe and asymptomatic individuals. (bakker2001humanαnacetylgalactosaminidase(αnaga) pages 4-5, bakker2001humanαnacetylgalactosaminidase(αnaga) pages 1-2)

Key statistics (from retrieved evidence)

Reported rarity: “fewer than 20 cases” described (as of 2019 case report). (castro2019anewcase pages 1-3)
Earlier reported counts: 11 known individuals (2001) and 12 patients from eight families (2004). (bakker2001humanαnacetylgalactosaminidase(αnaga) pages 1-2, sakuraba2004structuralandimmunocytochemical pages 1-2)
Severe type I survival: death often before age 6 years (case-based summary). (castro2019anewcase pages 1-3)
Urine glycomics biomarkers: GalNAc-threonine Z≈80, GalNAc-serine Z≈20 in Schindler disease in an LC-MS/MS biomarker panel. (mak2021detectinglysosomalstorage pages 8-9, mak2021detectinglysosomalstorage media 8ee1fda0)

Disease mapping / phenotype summary table

Disease entity / phenotype	Common names / synonyms	Key molecular cause	Defining clinical features	Notable variants cited	Key reference (year, journal, DOI/URL)	Evidence
NAGA deficiency spectrum	Schindler disease; α-N-acetylgalactosaminidase deficiency; α-NAGA deficiency; Schindler/Kanzaki disease	Biallelic pathogenic variants in NAGA causing deficient lysosomal α-N-acetylgalactosaminidase (α-NAGA) activity and impaired glycopeptide/glycolipid degradation	Broad spectrum from severe infantile neuroaxonal disease to mild adult angiokeratoma/lymphoedema phenotypes; marked genotype-phenotype variability and possible incomplete penetrance	*E325K, R329W, R329Q, E193X, c.577G>T (p.Glu193)**	Groopman et al., 2024, Molecular Genetics and Metabolism, https://doi.org/10.1016/j.ymgme.2024.108593	(groopman2024assessmentofgenes pages 8-11, castro2019anewcase pages 1-3, bakker2001humanαnacetylgalactosaminidase(αnaga) pages 1-2, sakuraba2004structuralandimmunocytochemical pages 1-2)
Type I phenotype	Schindler disease type I; infantile neuroaxonal dystrophy form	NAGA / α-NAGA deficiency	Early-onset severe phenotype; infantile neuroaxonal dystrophy with profound neurologic involvement; classically the most severe end of the spectrum	E325K homozygosis classically associated; severity not absolute	Wang et al., 1990, J Clin Invest, https://doi.org/10.1172/JCI114901; Sakuraba et al., 2004, J Hum Genet, https://doi.org/10.1007/s10038-003-0098-z	(sakuraba2004structuralandimmunocytochemical pages 1-2, wang1994themolecularlesion pages 1-2, bakker2001humanαnacetylgalactosaminidase(αnaga) pages 4-5)
Type II phenotype	Schindler disease type II; Kanzaki disease; adult-onset angiokeratoma form	NAGA / α-NAGA deficiency	Adult-onset mild phenotype with angiokeratoma corporis diffusum, vacuolization, lymphoedema, peripheral neuropathy, sensorineural hearing loss, often without overt central neurologic manifestations	*R329W, R329Q, E193X, c.577G>T (p.Glu193)**	Wang et al., 1994, J Clin Invest, https://doi.org/10.1172/JCI117404; Castro et al., 2019, EJCRIM, https://doi.org/10.12890/2019_001269	(castro2019anewcase pages 1-3, sakuraba2004structuralandimmunocytochemical pages 1-2, wang1994themolecularlesion pages 1-2, castro2019anewcase pages 3-3)
Type III phenotype	Schindler disease type III; NAGA deficiency type III; intermediate Schindler phenotype	NAGA / α-NAGA deficiency	Intermediate phenotype between type I and type II; literature describes variable neurologic/developmental involvement, seizures/behavioral problems/psychomotor delay in some reports, with possible systemic findings such as growth retardation, cardiomyopathy, or hepatomegaly in broader summaries	No single type III-specific recurrent variant established; variants reported across the spectrum include E325K, E193X and others	Bakker et al., 2001, Eur J Hum Genet, https://doi.org/10.1038/sj.ejhg.5200598; Sakuraba et al., 2004, J Hum Genet, https://doi.org/10.1007/s10038-003-0098-z	(bakker2001humanαnacetylgalactosaminidase(αnaga) pages 1-2, asadi2021theroleof pages 1-3, castro2019anewcase pages 1-3, sakuraba2004structuralandimmunocytochemical pages 1-2)
Molecular genetics / genotype-phenotype paradox	NAGA-related Schindler spectrum	NAGA gene; lysosomal hydrolase deficiency	Same or null alleles can present with dramatically different severity; asymptomatic or minimally affected individuals have been reported despite enzyme deficiency	E193X is a null allele yet reported in mild disease; E325K linked both to severe disease and apparently unaffected relatives; R329W causes inactive but immunoreactive protein	Keulemans et al., 1996, J Med Genet, https://doi.org/10.1136/jmg.33.6.458; Bakker et al., 2001, Eur J Hum Genet, https://doi.org/10.1038/sj.ejhg.5200598	(keulemans1996humanalphanacetylgalactosaminidase(alphanaga) pages 1-2, bakker2001humanαnacetylgalactosaminidase(αnaga) pages 1-2, wang1994themolecularlesion pages 1-2, bakker2001humanαnacetylgalactosaminidase(αnaga) pages 4-5)

Table: This table summarizes how NAGA deficiency type III maps onto the Schindler/Kanzaki disease spectrum, highlighting the shared molecular cause, phenotype distinctions across types I–III, and the main variants and references cited in the literature.

Limitations of this report (evidence constraints)

The retrieved excerpts did not contain explicit OMIM/Orphanet/ICD/MeSH codes; only MONDO:0017779 was directly evidenced via ClinGen-oriented literature. (groopman2024assessmentofgenes pages 8-11)
Type-III-specific phenotype frequencies are not well-quantified in the available literature due to very small sample sizes and overlapping clinical categories. (bakker2001humanαnacetylgalactosaminidase(αnaga) pages 1-2, sakuraba2004structuralandimmunocytochemical pages 1-2)

References

(groopman2024assessmentofgenes pages 8-11): Emily Groopman, Shruthi Mohan, Amber Waddell, Matheus Wilke, Raquel Fernandez, Meredith Weaver, Hongjie Chen, Hongbin Liu, Deeksha Bali, Heather Baudet, Lorne Clarke, Christina Hung, Rong Mao, Filippo Pinto e Vairo, Lemuel Racacho, Tatiana Yuzyuk, William J. Craigen, and Jennifer Goldstein. Assessment of genes involved in lysosomal diseases using the clingen clinical validity framework. Molecular Genetics and Metabolism, 143:108593, Nov 2024. URL: https://doi.org/10.1016/j.ymgme.2024.108593, doi:10.1016/j.ymgme.2024.108593. This article has 1 citations and is from a peer-reviewed journal.
(castro2019anewcase pages 1-3): Rubén García Castro, Ana María González Pérez, María Concepción Román Curto, Javier Cañueto Álvarez, Alberto Conde Ferreirós, Alex Viñolas Cuadros, David Moyano Bueno, and Antonio Javier Chamorro Fernández. A new case of schindler disease. European Journal of Case Reports in Internal Medicine, 6:1, Oct 2019. URL: https://doi.org/10.12890/2019_001269, doi:10.12890/2019_001269. This article has 12 citations.
(sakuraba2004structuralandimmunocytochemical pages 1-2): Hitoshi Sakuraba, Fumiko Matsuzawa, Sei-ichi Aikawa, Hirofumi Doi, Masaharu Kotani, Hiroshi Nakada, Tomoko Fukushige, and Tamotsu Kanzaki. Structural and immunocytochemical studies on α-n-acetylgalactosaminidase deficiency (schindler/kanzaki disease). Journal of Human Genetics, 49:1-8, Jan 2004. URL: https://doi.org/10.1007/s10038-003-0098-z, doi:10.1007/s10038-003-0098-z. This article has 60 citations and is from a peer-reviewed journal.
(bakker2001humanαnacetylgalactosaminidase(αnaga) pages 1-2): Henk D Bakker, Marie-Louise CS de Sonnaville, Peter Vreken, Nico GGM Abeling, Johanna EM Groener, Joke LM Keulemans, and Otto P van Diggelen. Human α-n-acetylgalactosaminidase (α-naga) deficiency: no association with neuroaxonal dystrophy? European Journal of Human Genetics, 9:91-96, Feb 2001. URL: https://doi.org/10.1038/sj.ejhg.5200598, doi:10.1038/sj.ejhg.5200598. This article has 54 citations and is from a domain leading peer-reviewed journal.
(keulemans1996humanalphanacetylgalactosaminidase(alphanaga) pages 1-2): J. Keulemans, A. Reuser, M. Kroos, R. Willemsen, M. Hermans, A. V. D. van den Ouweland, J. de Jong, R. Wevers, W. Renier, D. Schindler, M. Coll, A. Chabás, H. Sakuraba, Y. Suzuki, and O. V. van Diggelen. Human alpha-n-acetylgalactosaminidase (alpha-naga) deficiency: new mutations and the paradox between genotype and phenotype. Journal of Medical Genetics, 33:458-464, Jun 1996. URL: https://doi.org/10.1136/jmg.33.6.458, doi:10.1136/jmg.33.6.458. This article has 52 citations and is from a domain leading peer-reviewed journal.
(asadi2021theroleof pages 1-3): Shahin Asadi, Amir Houssein Kiani, and Mohaddeseh Mohsenifar. The role of mutations on gene naga, in schindler syndrome. Biomedical Research and Clinical Reviews, 3:01-04, Jan 2021. URL: https://doi.org/10.31579/2692-9406/029, doi:10.31579/2692-9406/029. This article has 0 citations.
(bakker2001humanαnacetylgalactosaminidase(αnaga) pages 4-5): Henk D Bakker, Marie-Louise CS de Sonnaville, Peter Vreken, Nico GGM Abeling, Johanna EM Groener, Joke LM Keulemans, and Otto P van Diggelen. Human α-n-acetylgalactosaminidase (α-naga) deficiency: no association with neuroaxonal dystrophy? European Journal of Human Genetics, 9:91-96, Feb 2001. URL: https://doi.org/10.1038/sj.ejhg.5200598, doi:10.1038/sj.ejhg.5200598. This article has 54 citations and is from a domain leading peer-reviewed journal.
(wang1994themolecularlesion pages 1-2): A. M. Wang, T. Kanzaki, and R. Desnick. The molecular lesion in the alpha-n-acetylgalactosaminidase gene that causes angiokeratoma corporis diffusum with glycopeptiduria. The Journal of clinical investigation, 94 2:839-45, Aug 1994. URL: https://doi.org/10.1172/jci117404, doi:10.1172/jci117404. This article has 35 citations.
(mak2021detectinglysosomalstorage pages 8-9): Justin Mak and Tina M. Cowan. Detecting lysosomal storage disorders by glycomic profiling using liquid chromatography mass spectrometry. Sep 2021. URL: https://doi.org/10.1016/j.ymgme.2021.08.006, doi:10.1016/j.ymgme.2021.08.006. This article has 30 citations and is from a peer-reviewed journal.
(mak2021detectinglysosomalstorage media 8ee1fda0): Justin Mak and Tina M. Cowan. Detecting lysosomal storage disorders by glycomic profiling using liquid chromatography mass spectrometry. Sep 2021. URL: https://doi.org/10.1016/j.ymgme.2021.08.006, doi:10.1016/j.ymgme.2021.08.006. This article has 30 citations and is from a peer-reviewed journal.
(castro2019anewcase pages 3-3): Rubén García Castro, Ana María González Pérez, María Concepción Román Curto, Javier Cañueto Álvarez, Alberto Conde Ferreirós, Alex Viñolas Cuadros, David Moyano Bueno, and Antonio Javier Chamorro Fernández. A new case of schindler disease. European Journal of Case Reports in Internal Medicine, 6:1, Oct 2019. URL: https://doi.org/10.12890/2019_001269, doi:10.12890/2019_001269. This article has 12 citations.
(lange2024systematicdiagnosisof pages 6-7): Martin Lange, Nicoleta Corcodel, and Falk Schwendicke. Systematic diagnosis of lysosomal storage diseases in patients with hepatosplenomegaly. Bulletin of Pioneering Researches of Medical and Clinical Science, 4:66-80, Jan 2024. URL: https://doi.org/10.51847/isa3beaurx, doi:10.51847/isa3beaurx. This article has 0 citations.
(bakker2001humanαnacetylgalactosaminidase(αnaga) pages 5-6): Henk D Bakker, Marie-Louise CS de Sonnaville, Peter Vreken, Nico GGM Abeling, Johanna EM Groener, Joke LM Keulemans, and Otto P van Diggelen. Human α-n-acetylgalactosaminidase (α-naga) deficiency: no association with neuroaxonal dystrophy? European Journal of Human Genetics, 9:91-96, Feb 2001. URL: https://doi.org/10.1038/sj.ejhg.5200598, doi:10.1038/sj.ejhg.5200598. This article has 54 citations and is from a domain leading peer-reviewed journal.
(asadi2021theroleof pages 3-4): Shahin Asadi, Amir Houssein Kiani, and Mohaddeseh Mohsenifar. The role of mutations on gene naga, in schindler syndrome. Biomedical Research and Clinical Reviews, 3:01-04, Jan 2021. URL: https://doi.org/10.31579/2692-9406/029, doi:10.31579/2692-9406/029. This article has 0 citations.
(naumchik2020theroleof pages 7-9): Brianna M. Naumchik, Ashish Gupta, Heather Flanagan-Steet, Richard A. Steet, Sara S. Cathey, Paul J. Orchard, and Troy C. Lund. The role of hematopoietic cell transplant in the glycoprotein diseases. Cells, 9:1411, Jun 2020. URL: https://doi.org/10.3390/cells9061411, doi:10.3390/cells9061411. This article has 28 citations.
(tajima2009useofa pages 1-2): Youichi Tajima, Ikuo Kawashima, Takahiro Tsukimura, Kanako Sugawara, Mayuko Kuroda, Toshihiro Suzuki, Tadayasu Togawa, Yasunori Chiba, Yoshifumi Jigami, Kazuki Ohno, Tomoko Fukushige, Takuro Kanekura, Kohji Itoh, Toya Ohashi, and Hitoshi Sakuraba. Use of a modified alpha-n-acetylgalactosaminidase in the development of enzyme replacement therapy for fabry disease. American journal of human genetics, 85 5:569-80, Nov 2009. URL: https://doi.org/10.1016/j.ajhg.2009.09.016, doi:10.1016/j.ajhg.2009.09.016. This article has 73 citations and is from a highest quality peer-reviewed journal.
(hulme2022schistosomamansoniαnacetylgalactosaminidase pages 1-2): Benjamin J. Hulme, Kathrin K. Geyer, Josephine E. Forde-Thomas, Gilda Padalino, Dylan W. Phillips, Wannaporn Ittiprasert, Shannon E. Karinshak, Victoria H. Mann, Iain W. Chalmers, Paul J. Brindley, Cornelis H. Hokke, and Karl F. Hoffmann. Schistosoma mansoni α-n-acetylgalactosaminidase (smnagal) regulates coordinated parasite movement and egg production. Jan 2022. URL: https://doi.org/10.1371/journal.ppat.1009828, doi:10.1371/journal.ppat.1009828. This article has 31 citations and is from a highest quality peer-reviewed journal.
(sakuraba2004structuralandimmunocytochemical pages 3-5): Hitoshi Sakuraba, Fumiko Matsuzawa, Sei-ichi Aikawa, Hirofumi Doi, Masaharu Kotani, Hiroshi Nakada, Tomoko Fukushige, and Tamotsu Kanzaki. Structural and immunocytochemical studies on α-n-acetylgalactosaminidase deficiency (schindler/kanzaki disease). Journal of Human Genetics, 49:1-8, Jan 2004. URL: https://doi.org/10.1007/s10038-003-0098-z, doi:10.1007/s10038-003-0098-z. This article has 60 citations and is from a peer-reviewed journal.
(clark2009the1.9a pages 1-2): Nathaniel E. Clark and Scott C. Garman. The 1.9 a structure of human alpha-n-acetylgalactosaminidase: the molecular basis of schindler and kanzaki diseases. Journal of molecular biology, 393 2:435-47, Oct 2009. URL: https://doi.org/10.1016/j.jmb.2009.08.021, doi:10.1016/j.jmb.2009.08.021. This article has 83 citations and is from a domain leading peer-reviewed journal.
(NCT01891422 chunk 1): Longitudinal Studies of the Glycoproteinoses. Greenwood Genetic Center. 2009. ClinicalTrials.gov Identifier: NCT01891422

Ask OpenScientist

OpenScientist Report

Mappings

Inheritance

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Biochemical Markers

Source YAML

References & Deep Research

References

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

Comprehensive research report: NAGA Deficiency Type 3 (Schindler disease type III)

Executive summary

1. Disease information

1.1 Overview

1.2 Key identifiers

1.3 Synonyms / alternative names

1.4 Evidence type (individual vs aggregated)

2. Etiology

2.1 Primary causal factors

2.2 Risk factors

2.3 Protective factors / gene–environment interactions

3. Phenotypes

3.1 Phenotype spectrum and type definitions

3.2 Example clinical features reported across the spectrum

3.3 Suggested HPO terms (based on reported clinical features)

4. Genetic / molecular information

4.1 Causal gene

4.2 Pathogenic variants (examples in primary literature)

4.3 Genotype–phenotype complexity and modifiers

5. Environmental information

6. Mechanism / pathophysiology

6.1 Core defect and causal chain

6.2 Biochemical abnormalities and stored material

6.3 Suggested GO biological process terms (mechanism-oriented)

6.4 Suggested Cell Ontology (CL) terms for implicated cell types

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population

10. Diagnostics

11. Outcome / prognosis

12. Treatment

12.1 Current standard of care

12.2 Emerging/experimental approaches

13. Prevention

14. Other species / natural disease

15. Model organisms and experimental systems

Recent developments and latest research (prioritizing 2023–2024)

Current applications and real-world implementations

Expert opinions and analysis (authoritative sources)

Key statistics (from retrieved evidence)

Disease mapping / phenotype summary table

Limitations of this report (evidence constraints)

Artifacts